The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 31, Issue 9, 2015, Pages 1693-1702

  Gavin, James R ^a   Davies, Melanie J ^b   Davies, Michael ^c   Vijapurkar, Ujjwala ^c   Alba, Maria ^c   Meininger, Gary ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Efficacy; Race; Safety; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AFRICAN AMERICAN; ALASKA NATIVE; AMERICAN INDIAN; ANCESTRY GROUP; ARTICLE; ASIA; BODY WEIGHT; CAUCASIAN; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL TRACT INFECTION; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOSIS; NATIVE HAWAIIAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PACIFIC ISLANDER; PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYURIA; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINARY TRACT INFECTION; AGED; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ETHNIC GROUP; ETHNOLOGY; GLUCOSE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84940775310     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1067192     Document Type: Article

References (38)

1. International Diabetes Federation. IDF Diabetes Atlas, Sixth edition, 2013. Available at: Http://www.idf.org/sites/default/files/EN-6E-Atlas-Exec-Sum-1.pdf [Last accessed 8 January 2015]
2. Kanaya AM, Herrington D, Vittinghoff E, et al. Understanding the high prevalence of diabetes in U.S. South Asians compared with four racial/ethnic groups: The MASALA and MESA studies. Diabetes Care 2014; 37: 1621-8
3. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: Relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001; 24: 1377-83
4. Dagogo-Jack S. Ethnic disparities in type 2 diabetes: Pathophysiology and implications for prevention and management. J Natl Med Assoc 2003; 95: 774-9
5. Gaillard TR, Osei K. Racial disparities in the pathogenesis of type 2 diabetes and its subtypes in the African diaspora: A new paradigm. J Racial Ethnic Health Disparities 2015; doi: 10.1007/s40615-015-0121-z. Published online 16 May 2015
6. Selvin E, Steffes MW, Ballantyne CM, et al. Racial differences in glycemic markers: A cross-sectional analysis of community-based data. Ann Intern Med 2011; 154: 303-9
7. Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30: 2453-7
8. Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: A cross-sectional analysis of 2 studies. Ann Intern Med 2010; 152: 770-7
9. Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-Anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1689-94
10. Mostafa SA, Davies MJ, Webb DR, et al. Independent effect of ethnicity on glycemia in South Asians and white Europeans. Diabetes Care 2012; 35: 1746-8
11. Wolffenbuttel BH, Herman WH, Gross JL, et al. Ethnic differences in glycemic markers in patients with type 2 diabetes. Diabetes Care 2013; 36: 2931-6
12. Lynch CP, Williams JL, Reid J, et al. Racial/ethnic differences in multiple diabetes outcomes in patients with type 2 diabetes in the southeastern United States. Ethn Dis 2014; 24: 189-94
13. Lopez JM, Bailey RA, Rupnow MF, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. Clin Ther 2014; 36: 494-506
14. Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-57
15. Premanath M, Basavanagowdappa H, Mahesh M, Suresh M. Correlation of abdominal adiposity with components of metabolic syndrome, anthropometric parameters and Insulin resistance, in obese and non obese, diabetics and non diabetics: A cross sectional observational study. (Mysore Visceral Adiposity in Diabetes Study). Indian J Endocrinol Metab 2014; 18: 676-82
16. Banerji MA, Faridi N, Atluri R, et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999; 84: 137-44
17. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43
18. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-Transport (SGLT) inhibitors: Systematic review and meta-Analysis of randomized trials. Ann Med 2012; 44: 375-93
19. Matthews D, Zinman B, Tong C, et al. Glycemic efficacy of canagliflozin (CANA) is largely independent of baseline beta-cell function or insulin sensitivity [abstract 1096-P]. Diabetes 2014; 63(Suppl 1): A285
20. Bakker LE, Sleddering MA, Schoones JW, et al. Pathogenesis of type 2 diabetes in South Asians. Eur J Endocrinol 2013; 169: R99-114
21. Bacha F, Gungor N, Lee S, Arslanian SA. Type 2 diabetes in youth: Are there racial differences in b-cell responsiveness relative to insulin sensitivity? Pediatr Diabetes 2012; 13: 259-65
22. Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes 2002; 51(Suppl 1): S262-4
23. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-82
24. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013; 56: 2582-92
25. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract 2013; 67: 1267-82
26. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-77
27. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, doubleblind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-50
28. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) -A randomized placebo-controlled trial. Am Heart J 2013; 166: 217-33
29. Fulcher G, Matthews D, Perkovic V, et al. Canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled on sulfonylurea (SU) monotherapy: A CANVAS substudy [abstract 1124-P]. Diabetes 2013; 62(Suppl 1): A292
30. Rosenstock J, Davies M, Dumas R, et al. Effects of canagliflozin added on to basal insulin+/-other antihyperglycemic agents in type 2 diabetes [abstract 1084-P]. Diabetes 2013; 62(Suppl 1): A280
31. Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Investig 2015; 6: 210-18
32. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6: 453-67
33. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-Transporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-19
34. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 473-8
35. Ahrén B, Mathieu C, Bader G, et al. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: Comparison of results from randomised controlled and observational studies. Diabetologia 2014; 57: 1304-7
36. Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: A post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract 2010; 16: 818-28
37. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247-56
38. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-Analysis. Diabetologia 2013; 56: 696-708